Skip to main content
Erschienen in: International Journal of Colorectal Disease 7/2022

27.05.2022 | Original Article

Efficacy of risk-stratified indicators for adjuvant chemotherapy with fluorouracil and oxaliplatin after hepatectomy for colorectal cancer liver metastasis

verfasst von: Keizaburo Maruyama, Tetsuro Tominaga, Takashi Nonaka, Masaaki Moriyama, Shosaburo Oyama, Mitsutoshi Ishii, Terumitsu Sawai, Takeshi Nagayasu

Erschienen in: International Journal of Colorectal Disease | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

The recurrence rate after hepatectomy for colorectal cancer liver metastasis (CRLM) is high, and there is no consensus regarding the effect of adjuvant chemotherapy (AC) using oxaliplatin (doublet AC) in these patients.

Methods

The present study included 91 patients who underwent hepatectomy for complete resection at our hospitals between 2008 and 2018. Based on whether or not they had undergone doublet AC, patients were divided into AC (n = 35) and non-AC (n = 56) groups. The recurrent risk was evaluated by the Memorial Sloan Kettering Cancer Center clinical risk score (MSKCC-CRS).

Results

The number of females and median age were higher in the AC group (51.4% vs 25.0%, p = 0.010 and 67 vs 61 years, p = 0.012, respectively). The median follow-up period was 45 months (range, 6–101 months). Doublet AC was an independent prognostic factor for 5-year relapse-free survival (hazard ratio, 0.225; 95%CI, 0.097–0.522; p < 0.001) and for 5-year overall survival (hazard ratio, 0.165; 95%CI, 0.057–0.476; p < 0.001) in multivariate analysis. In patients with a high risk of recurrence (MSKCC-CRS 3–5), 5-year relapse-free survival and 5-year overall survival was higher in the doublet AC group than in the non-AC group (p < 0.01). In low-risk patients (MSKCC-CRS 0–2), 5-year relapse-free survival and 5-year overall survival were similar between the groups.

Conclusions

Doublet AC could have a positive effect on prognosis after curative resection of CRLM, especially in high-risk patients. The selection of patients and AC regimen should take into consideration the risk of recurrence.
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC et al (2020) Cancer statistics, 2020. CA Cancer J Clin 70:145–164CrossRef Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC et al (2020) Cancer statistics, 2020. CA Cancer J Clin 70:145–164CrossRef
2.
Zurück zum Zitat Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4:448–456CrossRef Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4:448–456CrossRef
3.
Zurück zum Zitat Adam R, Vinet E (2004) Regional treatment of metastasis: surgery of colorectal liver metastases. Ann Oncol 15 Suppl 4: iv103-iv106. Adam R, Vinet E (2004) Regional treatment of metastasis: surgery of colorectal liver metastases. Ann Oncol 15 Suppl 4: iv103-iv106.
4.
Zurück zum Zitat Ito K, Govindarajan A, Ito H, Fong Y (2010) Surgical treatment of hepatic colorectal metastasis: evolving role in the setting of improving systemic therapies and ablative treatments in the 21st century. Cancer J 16:103–110CrossRef Ito K, Govindarajan A, Ito H, Fong Y (2010) Surgical treatment of hepatic colorectal metastasis: evolving role in the setting of improving systemic therapies and ablative treatments in the 21st century. Cancer J 16:103–110CrossRef
5.
Zurück zum Zitat Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318CrossRef Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318CrossRef
6.
Zurück zum Zitat Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR et al (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–825CrossRef Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR et al (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–825CrossRef
7.
Zurück zum Zitat Beppu T, Sakamoto Y, Hasegawa K, Honda G, Tanaka K, Kotera Y et al (2012) A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a project study for hepatic surgery of the Japanese 14 Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 19:72–84CrossRef Beppu T, Sakamoto Y, Hasegawa K, Honda G, Tanaka K, Kotera Y et al (2012) A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a project study for hepatic surgery of the Japanese 14 Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 19:72–84CrossRef
8.
Zurück zum Zitat André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351CrossRef André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351CrossRef
9.
Zurück zum Zitat Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clinic Oncol : Official J Am Soc Clinic Oncol 25:2198–2204CrossRef Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clinic Oncol : Official J Am Soc Clinic Oncol 25:2198–2204CrossRef
10.
Zurück zum Zitat Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E et al (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clinic Oncol : Official J Am Soc Clinic Oncol 29:1465–1471CrossRef Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E et al (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clinic Oncol : Official J Am Soc Clinic Oncol 29:1465–1471CrossRef
11.
Zurück zum Zitat Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C et al (2009) A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 20:1964–1970CrossRef Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C et al (2009) A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 20:1964–1970CrossRef
12.
Zurück zum Zitat Lorenz M, Müller HH, Schramm H, Gassel HJ, Rau HG, Ridwelski K et al (1998) Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 228:756–762CrossRef Lorenz M, Müller HH, Schramm H, Gassel HJ, Rau HG, Ridwelski K et al (1998) Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 228:756–762CrossRef
13.
Zurück zum Zitat Rudroff C, Altendorf-Hoffmann A, Stangl R, Scheele J (1999) Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases. Langenbecks Arch Surg 384:243–249CrossRef Rudroff C, Altendorf-Hoffmann A, Stangl R, Scheele J (1999) Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases. Langenbecks Arch Surg 384:243–249CrossRef
14.
Zurück zum Zitat Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V, Schlag PM (2009) Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol Immunother 58:61–69CrossRef Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V, Schlag PM (2009) Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol Immunother 58:61–69CrossRef
15.
Zurück zum Zitat Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y et al (2018) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 23:1–34CrossRef Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y et al (2018) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 23:1–34CrossRef
16.
Zurück zum Zitat Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS et al (2017) Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compre Cancer Network : JNCCN 15:370–398CrossRef Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS et al (2017) Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compre Cancer Network : JNCCN 15:370–398CrossRef
17.
Zurück zum Zitat Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386–1422CrossRef Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386–1422CrossRef
18.
Zurück zum Zitat Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 233:309–318CrossRef Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 233:309–318CrossRef
19.
Zurück zum Zitat Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J et al (2006) Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clinic Oncol : Official J Am Soc Clinic Oncol 24:4976–4982CrossRef Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J et al (2006) Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clinic Oncol : Official J Am Soc Clinic Oncol 24:4976–4982CrossRef
20.
Zurück zum Zitat Hasegawa K, Saiura A, Takayama T, Miyagawa S, Yamamoto J, Ijichi M et al (2016) Adjuvant oral uracil-tegafur with leucovorin for colorectal cancer liver metastases: a randomized controlled trial. PLoS ONE 11:e0162400CrossRef Hasegawa K, Saiura A, Takayama T, Miyagawa S, Yamamoto J, Ijichi M et al (2016) Adjuvant oral uracil-tegafur with leucovorin for colorectal cancer liver metastases: a randomized controlled trial. PLoS ONE 11:e0162400CrossRef
21.
Zurück zum Zitat Kanemitsu Y, Shimizu Y, Mizusawa J, Inaba Y, Hamaguchi T, Shida D et al (2021) Hepatectomy followed by mFOLFOX6 versus hepatectomy alone for liver-only metastatic colorectal cancer (JCOG0603): a phase II or III randomized controlled trial. J Clinic Oncol : Official J Am Soc Clinic Oncol 39:3789–3799CrossRef Kanemitsu Y, Shimizu Y, Mizusawa J, Inaba Y, Hamaguchi T, Shida D et al (2021) Hepatectomy followed by mFOLFOX6 versus hepatectomy alone for liver-only metastatic colorectal cancer (JCOG0603): a phase II or III randomized controlled trial. J Clinic Oncol : Official J Am Soc Clinic Oncol 39:3789–3799CrossRef
22.
Zurück zum Zitat Uehara K, Maeda A, Sakamoto E, Hiramatsu K, Takeuchi E, Sakaguchi K et al (2013) Phase II trial of adjuvant chemotherapy with S-1 for colorectal liver metastasis. Ann Surg Oncol 20:475–481CrossRef Uehara K, Maeda A, Sakamoto E, Hiramatsu K, Takeuchi E, Sakaguchi K et al (2013) Phase II trial of adjuvant chemotherapy with S-1 for colorectal liver metastasis. Ann Surg Oncol 20:475–481CrossRef
23.
Zurück zum Zitat Hirokawa F, Hayashi M, Miyamoto Y, Asakuma M, Shimizu T, Komeda K et al (2014) Reconsideration of the indications for adjuvant chemotherapy for liver metastases from colorectal cancer after initial hepatectomy. Ann Surg Oncol 21:139–146CrossRef Hirokawa F, Hayashi M, Miyamoto Y, Asakuma M, Shimizu T, Komeda K et al (2014) Reconsideration of the indications for adjuvant chemotherapy for liver metastases from colorectal cancer after initial hepatectomy. Ann Surg Oncol 21:139–146CrossRef
24.
Zurück zum Zitat Pan Z, Peng J, Lin J, Chen G, Wu X, Lu Z et al (2018) Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection? Cancer Commun (London, England) 38:29CrossRef Pan Z, Peng J, Lin J, Chen G, Wu X, Lu Z et al (2018) Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection? Cancer Commun (London, England) 38:29CrossRef
25.
Zurück zum Zitat Margalit O, Boursi B, Rakez M, Thierry A, Yothers G, Wolmark N et al (2021) Benefit of oxaliplatin in stage III colon cancer according to IDEA Risk Groups: findings from the ACCENT database of 4934 patients. Clin Colorectal Cancer 20:130–136CrossRef Margalit O, Boursi B, Rakez M, Thierry A, Yothers G, Wolmark N et al (2021) Benefit of oxaliplatin in stage III colon cancer according to IDEA Risk Groups: findings from the ACCENT database of 4934 patients. Clin Colorectal Cancer 20:130–136CrossRef
Metadaten
Titel
Efficacy of risk-stratified indicators for adjuvant chemotherapy with fluorouracil and oxaliplatin after hepatectomy for colorectal cancer liver metastasis
verfasst von
Keizaburo Maruyama
Tetsuro Tominaga
Takashi Nonaka
Masaaki Moriyama
Shosaburo Oyama
Mitsutoshi Ishii
Terumitsu Sawai
Takeshi Nagayasu
Publikationsdatum
27.05.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Colorectal Disease / Ausgabe 7/2022
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-022-04189-5

Weitere Artikel der Ausgabe 7/2022

International Journal of Colorectal Disease 7/2022 Zur Ausgabe

TAVI bei kleinem Aortenklappenanulus: Es gibt noch ungeklärte Fragen

13.06.2024 TAVI Nachrichten

Zwischen selbstexpandierenden und ballonexpandierbaren TAVI-Klappen scheinen bezüglich der Klappenfunktion bei Aortenstenose und kleinem Aortenklappenanulus Unterschiede zu bestehen. Aber sind die überhaupt von klinischer Relevanz? Eine neue Studie liefert dazu Informationen.

Fortgeschrittenes Ovarial-Ca.: Unverdächtige Lymphknoten entfernen?

13.06.2024 ASCO 2024 Kongressbericht

Beim fortgeschrittenen Ovarialkarzinom und klinisch verdächtigen Lymphknoten in der Debulking-Op. ist die abdominale retroperitoneale Lymphadenektomie (RPL) Standard. Ohne verdächtige Lymphknoten ist der Nutzen fraglich.

Auch ohne Blutung: Hämoglobinabfall nach TAVI ein Warnzeichen

10.06.2024 TAVI Nachrichten

Kommt es nach einem Transkatheter-Aortenklappen-Ersatz zu einem deutlichen Rückgang der Hämoglobinwerte, obwohl keine Blutung vorliegt, ist die Kliniksterblichkeit ähnlich hoch wie bei einem Rückgang mit Blutung. 

Nierenspende stellt kein Risiko für Hypertonie dar

07.06.2024 Nierentransplantation Nachrichten

Wer im Zuge einer Lebendspende eine seiner Nieren an eine Person im Nierenversagen weitergibt, muss nicht fürchten, sich damit ein erhöhtes Hypertonierisiko einzuhandeln. Auch Albuminurie tritt nicht häufiger auf, wie eine Studie zeigt.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.